Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TLC399 in Macular Edema Due to RVO
NCT03093701Phase 2Completed
- Sponsor
- Taiwan Liposome Company
- Start
- Apr 2017
- Primary completion
- Feb 2019
- Modality
- Small Molecules, Lipid-based Nanoparticles
- Countries
- 1
01
Overview
A Phase 2 trial of ProDex in macular edema, sponsored by Taiwan Liposome Company. Started Apr 2017; status: completed.
02
Drugs
ProDex
03
Conditions
macular edema
Beyond the preview
Go deeper on NCT03093701.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03093701.